Clinical trials represent one of the most powerful tools to address important diagnostic and therapeutic questions in clinical research. Despite their critical role, enrollment rates to adult cancer clinical trials remain low in the US. The increasing complexity of cancer clinical trials has lengthened the time and intensified the effort required for their activation and conduct. In order to optimize clinical trial activities in hematological malignancies, challenges related to trial initiation and recruitment must be recognized and systematically addressed.

In this session, Dr. Siu will review potential barriers to clinical trial enrollment including physician and patient factors, difficulties related to trial logistics, protocol restrictions, among others, and will discuss possible solutions to overcome some of these issues.

Dr. Farrell will review perceived regulatory barriers for clinical trial approvals, regulatory requirements for clinical trials used to provide data for licensing applications and discuss potential global solutions.